Last updated: July 23, 2026

Does Aetna Cover ADHD Treatment in Delaware? A 2026 Guide

If you have Aetna insurance in Delaware and you or a family member has been diagnosed with attention-deficit/hyperactivity disorder (ADHD), understanding your coverage may save you hundreds. Or even thousands. Of dollars each year. Aetna is a major commercial insurer in Delaware, and its pharmacy benefits are administered through CVS/Caremark. This guide explains how Delaware’s mental health parity law applies to ADHD, what the CVS/Caremark formulary typically covers, which medications require prior authorization, and how Delaware’s Electronic Prescribing of Controlled Substances (EPCS) rules affect your prescriptions.

Ready to connect with a licensed ADHD provider who accepts Aetna? See if your Aetna plan may cover ADHD treatment at Klarity →

Key facts at a glance

• Insurer: Aetna (Delaware commercial and Medicare Advantage plans)
• PBM: CVS/Caremark
• State parity law: Del. Code Ann. tit. 18, § 3343 (ADHD is a covered mental health condition under MHPAEA-aligned parity)
• Delaware EPCS: Schedule II stimulants (Adderall, Ritalin, Vyvanse, Concerta, Dexedrine) = EPCS REQUIRED. Non-stimulants (Strattera, Qelbree, Intuniv, Kapvay) are non-scheduled = EPCS inapplicable.
• PA requirement: Generic stimulants typically no PA; brand stimulants and most non-stimulants require PA + possible step therapy
• Aetna member services: 1-800-872-3862
• CVS/Caremark: 1-800-552-8159
• Delaware Department of Insurance: 1-302-674-7300

Delaware Mental Health Parity Law and ADHD Coverage

Delaware’s mental health parity statute, Del. Code Ann. tit. 18, § 3343, requires that state-regulated commercial health insurers, including most Aetna individual and fully insured group plans sold in Delaware, provide mental health and substance use disorder benefits that are no more restrictive than comparable medical/surgical benefits. The statute aligns Delaware law with the federal Mental Health Parity and Addiction Equity Act (MHPAEA). ADHD is recognized as a mental health condition under the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and is subject to these parity protections.

In practical terms, § 3343 means:

• Aetna may not impose higher copays, stricter prior authorization criteria, or lower visit limits for ADHD treatment than it does for comparable physical health conditions
• Quantitative treatment limitations (visit caps, day limits) and non-quantitative treatment limitations (medical necessity criteria, step therapy requirements) must be comparable
• If you believe Aetna is applying more restrictive criteria to your ADHD care than to analogous medical care, you have a right to request a parity analysis and file a complaint with the Delaware Department of Insurance

Important note: § 3343 applies to state-regulated, fully insured commercial plans. ERISA-governed self-funded employer plans are subject to federal MHPAEA rather than Delaware state law, though the substantive protections are similar. For ERISA plan disputes, contact the U.S. Department of Labor EBSA at 1-866-444-3272.

How Aetna Covers ADHD Treatment in Delaware

Aetna’s ADHD coverage typically includes the following categories of care, subject to your specific plan’s terms:

Medical/Behavioral Health Benefits

• Diagnostic evaluation: Psychiatric or psychological evaluation for ADHD diagnosis, subject to in-network copay/coinsurance
• Outpatient visits: Ongoing medication management appointments with a psychiatrist, primary care physician, or licensed prescriber
• Telehealth: Virtual ADHD evaluation and medication management visits are typically covered at parity with in-person visits under Aetna’s telehealth policy and Delaware parity rules
• Behavioral therapy: Individual therapy, cognitive behavioral therapy (CBT), and behavioral skills training for ADHD are typically covered as outpatient mental health benefits
• Neuropsychological testing: Comprehensive testing may be covered with prior authorization when medically necessary for diagnosis or treatment planning

Pharmacy Benefits (CVS/Caremark)

Aetna’s pharmacy benefits for ADHD medications are managed by CVS/Caremark. Coverage and cost-sharing depend on your specific plan’s formulary tier, deductible status, and any applicable prior authorization or step therapy requirements. The table below reflects typical CVS/Caremark formulary placement for common ADHD medications; always verify your specific plan’s formulary at aetna.com or by calling CVS/Caremark at 1-800-552-8159.

Formulary tiers and PA requirements are subject to change. Always verify your specific Aetna plan’s drug list before prescribing or filling a prescription.

Delaware EPCS Rules for ADHD Medications

Delaware requires electronic prescribing for controlled substances under Board of Medical Licensure and related controlled-substance rules (including DE Admin Code Title 24 § 1700 guidance for Schedule II substances). For ADHD, the practical split is clear.

What this means for ADHD stimulant medications

All Schedule II ADHD stimulants, including amphetamine salts (Adderall and generics), methylphenidate (Ritalin, Concerta, and generics), lisdexamfetamine (Vyvanse and generics), dextroamphetamine (Dexedrine), and mixed amphetamine salts extended release (Mydayis), are subject to Delaware’s EPCS requirement. Prescriptions for these medications must be sent electronically by a DEA-registered, EPCS-certified prescriber. Paper prescriptions are generally not permitted except in narrow exemptions (technological failure, facility limitations, and similar exceptions).

What this means for non-stimulant ADHD medications

Non-stimulant ADHD medications, atomoxetine (Strattera/generic), viloxazine ER (Qelbree), guanfacine ER (Intuniv/generic), and clonidine ER (Kapvay), are not controlled substances under federal or Delaware law. Delaware’s EPCS mandate is entirely inapplicable to these medications. They may be prescribed electronically or on paper at the prescriber’s discretion.

Klarity and EPCS compliance

Klarity’s licensed Delaware prescribers are DEA-registered and use EPCS-certified platforms for all controlled substance prescriptions, including Schedule II ADHD stimulants. You can receive your Adderall or Ritalin prescription electronically without an in-person visit, subject to your prescriber’s clinical judgment and applicable Delaware telehealth prescribing rules.

Prior Authorization for ADHD Medications Under Aetna/CVS/Caremark

Prior authorization (PA) is a process by which your insurance carrier reviews a medication before approving coverage. Under Aetna’s CVS/Caremark formulary, PA requirements for ADHD medications typically work as follows:

Medications that typically do NOT require PA

• Generic immediate-release amphetamine salts (generic Adderall)
• Generic extended-release amphetamine salts (generic Adderall XR)
• Generic methylphenidate (immediate-release and extended-release)

Medications that typically DO require PA

• Brand-name stimulants (Adderall XR brand, Vyvanse brand, Concerta brand): PA + step therapy. Aetna/CVS/Caremark typically requires documented trial of a generic equivalent before approving the brand-name version unless there is a clinically documented reason the generic is inadequate (for example, inactive ingredient allergy or demonstrated bioavailability difference).
• Generic lisdexamfetamine (generic Vyvanse): May require PA depending on plan tier; check your specific formulary.
• Atomoxetine (generic Strattera): PA required. CVS/Caremark typically requires documentation of ADHD diagnosis, clinical rationale for non-stimulant preference (stimulant intolerance, history of substance use disorder, comorbid tic disorder), and medical necessity review.
• Qelbree (viloxazine ER): PA required. As a newer branded non-stimulant, Qelbree typically requires step therapy documentation of prior stimulant or atomoxetine trial.
• Guanfacine ER / Clonidine ER: May require PA on some plans, particularly as adjunctive therapy.

PA criteria Aetna/CVS/Caremark commonly applies

• Confirmed diagnosis of ADHD (DSM-5 criteria documented in medical record)
• Age-appropriate criteria (adult vs. pediatric dosing and formulation considerations)
• For brand medications: documented trial and failure/intolerance of the generic equivalent
• For non-stimulants: clinical rationale for non-stimulant approach when a stimulant would typically be first-line
• Prescriber specialty or documentation supporting the diagnosis for more complex presentations

How to start a PA with Aetna/CVS/Caremark

1. Your prescriber submits the PA request through CoverMyMeds, the CVS/Caremark provider portal, or by fax using the plan-specific form.
2. Include diagnosis documentation, prior medication trials, and a letter of medical necessity when requesting brand or non-formulary agents.
3. Track the request status in the Aetna member portal or by calling CVS/Caremark at 1-800-552-8159.
4. Standard PA decisions are typically issued within several business days; urgent requests may qualify for expedited review.
5. If denied, request the written denial reason and initiate peer-to-peer or formal appeal (see below).

Step-by-Step: How to Verify Your Aetna ADHD Coverage in Delaware

1. Log in to your Aetna member portal at aetna.com. Navigate to Benefits → Pharmacy → Drug Cost & Coverage Tool. Enter your specific ADHD medication to see your plan’s tier, estimated cost, and any PA requirements.
2. Call Aetna member services at 1-800-872-3862. Ask specifically: (a) Is [medication name] covered under my plan? (b) What tier is it on? (c) Is prior authorization required? (d) Are there step therapy requirements? Request a reference number for the call.
3. Call CVS/Caremark at 1-800-552-8159 to verify pharmacy benefit details and confirm EPCS requirements for any Schedule II stimulant prescription.
4. Confirm your provider is in-network. Aetna’s network includes physicians, psychiatrists, nurse practitioners, and physician assistants. Klarity’s Delaware providers can be verified through Aetna’s find-a-doctor tools.
5. Request a Summary of Benefits and Coverage (SBC) if you are unsure of your exact plan terms. Your employer HR department or Aetna member services can provide this document.

What to Do If Aetna Denies Your ADHD Claim or PA Request

If Aetna denies coverage, a PA request, or a step therapy exception for an ADHD medication, you have the right to appeal. Delaware law and Aetna’s internal appeals process provide a structured pathway:

1. Request the denial letter in writing. Aetna must provide a written explanation of the denial, including the specific clinical criteria applied and the plan provision cited. You have the right to request the full clinical guidelines used to make the decision.
2. Peer-to-peer review. Your prescribing provider may request a peer-to-peer call with Aetna’s medical director or reviewing clinician. This is often the fastest way to overturn a PA denial and should be the first step for clinical disputes.
3. File a formal internal appeal. Submit clinical documentation: diagnosis records, treatment history, letter of medical necessity from your provider, and any supporting literature. Track deadlines on your denial letter carefully.
4. Request a parity analysis. If the denial involves ADHD medication management and you believe Aetna would not impose the same restrictions on a comparable physical health condition, request a written parity analysis under § 3343 and MHPAEA. File a parity complaint with the Delaware Department of Insurance if the analysis reveals a disparity.
5. External review / ERISA pathway. If Aetna upholds the denial after your internal appeal, fully insured Delaware plans may qualify for external review through the Delaware Department of Insurance (1-302-674-7300). Self-funded ERISA plans should contact DOL EBSA at 1-866-444-3272.

Delaware Department of Insurance: 1-302-674-7300 | insurance.delaware.gov

U.S. Department of Labor EBSA (for ERISA plans): 1-866-444-3272

Get Started with Aetna-Accepted ADHD Treatment in Delaware

Klarity connects Delaware residents with licensed ADHD providers, including psychiatrists, nurse practitioners, and physician assistants, who are experienced with Aetna coverage and CVS/Caremark PA requirements. Our providers are EPCS-certified and can send Schedule II stimulant prescriptions electronically in compliance with Delaware law.

• 100% telehealth. No commute, no waiting room
• Initial evaluation and ongoing medication management available
• Providers who understand Delaware’s § 3343 parity protections and can support PA appeals with clinical documentation
• 2,000+ licensed providers nationwide, including Delaware-licensed clinicians

Check if your Aetna plan may cover ADHD treatment at Klarity →

Frequently Asked Questions

Does Aetna cover telehealth ADHD treatment in Delaware?

Aetna typically covers telehealth ADHD evaluation and medication management at parity with in-person visits when the service is medically necessary and the provider is in-network or otherwise eligible under your plan. Coverage details vary by plan; verify with Aetna at 1-800-872-3862 before your first appointment.

Does Aetna cover Vyvanse (lisdexamfetamine) in Delaware?

Generic lisdexamfetamine (the generic for Vyvanse) may be covered at Tier 2. 3 under CVS/Caremark’s formulary with possible PA requirements. Brand-name Vyvanse is typically Tier 3. 4 and requires PA plus documented step therapy. Your prescriber can submit a PA request with clinical documentation of medical necessity. All lisdexamfetamine products are Schedule II, so Delaware EPCS is required.

Do I need prior authorization for generic Adderall on Aetna?

Generic amphetamine salts (generic Adderall and Adderall XR) typically do not require prior authorization on many Aetna/CVS/Caremark formularies, though quantity limits and age-related criteria may still apply. Always confirm on your specific plan’s drug list.

Does Delaware mental health parity apply to my Aetna ADHD benefits?

For fully insured commercial Aetna plans regulated by Delaware, Del. Code Ann. tit. 18, § 3343 generally requires mental health benefits, including ADHD care, to be no more restrictive than comparable medical/surgical benefits. Self-funded employer plans are governed by federal MHPAEA instead. Coverage still varies by plan design, so verify benefits before booking.

Can a Klarity provider prescribe ADHD stimulants in Delaware?

Licensed Delaware Klarity providers who are DEA-registered and EPCS-certified may prescribe Schedule II ADHD stimulants electronically when clinically appropriate. Non-stimulant options may also be considered. Klarity has 2,000+ licensed providers in its network nationwide.

What if my employer plan is self-funded (ERISA)?

§ 3343 may not apply to self-funded ERISA plans. Federal MHPAEA still applies. For appeals and parity concerns on ERISA plans, contact Aetna’s internal appeals process and DOL EBSA at 1-866-444-3272.

Key Contacts

• Aetna member services: 1-800-872-3862
• CVS/Caremark pharmacy benefits: 1-800-552-8159
• Delaware Department of Insurance: 1-302-674-7300
• U.S. Department of Labor EBSA (ERISA plans): 1-866-444-3272
• Klarity ADHD treatment: helloklarity.com/service/adhd-treatment

Disclaimer: This guide is for educational purposes only and does not constitute medical, legal, or insurance advice. Insurance coverage varies by plan, employer arrangement, formulary year, and individual medical necessity determinations. Always verify your specific Aetna benefits, prior authorization requirements, and cost-sharing with Aetna and CVS/Caremark before seeking care or filling a prescription. Klarity Health does not guarantee that any specific plan will cover any specific service or medication.